Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-S
DRKS00021080Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of andexanet alfa in anticoagulation therapy (2 arms), sponsored by Alexion Pharmaceuticals. Started Dec 2020; status: terminated.
02
Drugs
andexanet alfa
03
Conditions
anticoagulation therapy
Beyond the preview
Go deeper on DRKS00021080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00021080.